Category: Edwards Lifesciences
Medtech titan Medtronic plans to seek immediate appeal of a preliminary court injunction banning sales of its CoreValve transcatheter aortic valve implantation system.
Edwards Lifesciences lands a preliminary injunction limiting Medtronic from selling its CoreValve transcatheter aortic valve implantation system in the U.S.
California-based Edwards Lifesciences launches commercial efforts after winning European CE Mark approval for its next-generation INTUITY Elite surgical aortic valve.
Edwards Lifesciences (NYSE:EW) announced today that it won CE Mark approval in the European Union to market its next-generation INTUITY Elite aortic valve.
More results from Medtronic's hypertension studies continue to muddle the outlook for renal denervation as medtech titans vie for prime listing for their transcatheter valves.
The American College of Cardiology's annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic's (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.
Here's a look at some of the top Wall Street stories for medical device companies this week.
, American College of Cardiology
, Arterial Remodeling Technologies
, Baxter International
, Edwards Lifesciences
, K-C Health Care
, Kimberly-Clark Worldwide Inc.
, Smith & Nephew
, Terumo Corp.
, Urologix Inc.
, Abbott Laboratories
Edwards Lifesciences' Sapien XT replacement heart valve bests Medtronic's CoreValve in a small head-to-head study presented at the American College of Cardiology's annual conference.
UPDATED March 31, 2014, with comment from Medtronic
Edwards Lifesciences says the 1st 3 patients worldwide were implanted with its Fortis transcatheter mitral valve implant.
Edwards Lifesciences (NYSE:EW) said a surgical team at London's St. Thomas' Hospital implanted the 1st 3 patients with its Fortis transcatheter mitral valve implant.